Search

Your search keyword '"Bir, Ferda"' showing total 6 results
Start Over Author "Bir, Ferda" Topic immunohistochemistry
6 results on '"Bir, Ferda"'

1. Imumunohistochemical analysis of CD133 and nucleostemin in squamous cell carcinoma and adenocarcinoma.

Author

Tan, Semih, Cetin, Hulya, Bir, Ferda, Oncel, Sevin Baser, and Dogu, Gamze Gokoz

Subjects
NON-small-cell lung carcinoma, NEURAL stem cells, DISEASE progression, IMMUNOHISTOCHEMISTRY
Abstract

Aim: Cancer stands as a significant health issue in our era, with lung cancer being among the most widespread types in both Turkey and worldwide. The diagnosis may be delayed due to the late detection of symptoms and signs. Cancer stem cells cause the initiation and progression of cancer. There is a risk of cancer recurrence due to cancer stem cells that cannot be destroyed. Therefore, it is important to detect cancer stem cells and prevent the proliferation of these stem cells. Materials and Methods: In the Pathology Department of Pamukkale University Faculty of Medicine, 72 squamous cell carcinoma and 51 adenocarcinoma cases diagnosed with non-small cell lung cancer were retrospectively examined. Nucleostemin and CD133 expression levels were evaluated immunohistochemically in sections taken from cancerous tissue samples of the cases. Results: Disease-free survival and tumor stages of the cases and immunohistochemical expression level were compared. Nucleostemin and CD133 expression was commonly observed in tumor tissue from both adenocarcinoma and squamous cell carcinoma cases. Conclusion: Therefore, in line with the data we obtained, we think that both nucleostemin and CD133 cannot be used as prognostic markers in non-small cell lung cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma.

Author

Karakaya, Yeliz Arman, Dogu, Gamze Gokoz, Oncel, Sevin Baser, Gormez, Aysegul, and Bir, Ferda

Subjects
CARCINOMA, BIOMARKERS, CANCER chemotherapy, FLUORESCENCE, FLUORESCENCE in situ hybridization
Abstract

Aim: The excision repair cross-complementation group 1 (ERCC-1) protein is a potential prognostic biomarker of the efficacy of platinum-based chemotherapy in non-small-cell lung cancer (NSCLC). The purpose of this study was to evaluate the clinicopathology and prognostic significance of ERCC-1 expression, ERCC-1 (19q13) amplification in NSCLC patients; and the relationship between platinum-based chemotherapy. Materials and Methods: We used the ERCC-1 antibody to measure the level of expression of ERCC-1 protein by immunohistochemical analysis from 351 patients and ERCC-1 gene copy number was evaluated by fluorescence in situ hybridization (FISH) in tumors from 81 patients. Results: ERCC-1 expression in tumor cells was positive in 312 patients (88.9%). The ERCC-1 amplification in tumor cells was positive in 58 patients (71.6%) out of 81. The ERCC-1 amplification was also more frequent in early-stage tumors than late-stage tumors (p = 0.025). In the patients with positive ERCC-1 expression, longer overall survival was associated with early stage NSCLC (p = 0.001). Patients having adenocarcinoma with negative ERCC-1 expression demonstrated longer overall survival than patients with squamous cell carcinoma (p = 0.037). Conclusion: Our study demonstrated that increased ERCC-1 amplification is not associated with ERCC-1 protein expression. High ERCC-1 expression in patients with early-stage NSCLC is a good prognostic factor, although it is a negative predictor, indicating treatment resistance, in patients with advanced-stage NSCLC receiving platinum-based chemotherapy. We suggest that patients having adenocarcinoma with negative ERCC-1 expression benefit more with platinum-based chemotherapies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

4. New immunohistochemical markers in the differential diagnosis of nonsmall cell lung carcinoma.

Author

BİR, Ferda, ÇELİKER, Duygu, EVYAPAN, Binnaz Fatma, YAREN, Arzu, and EDİRNE, Tamer

Subjects
*DESMOGLEINS, *IMMUNOHISTOCHEMISTRY, *BIOMARKERS, *LUNG cancer patients, *PATIENT acceptance of health care
Abstract

Background/aim: The aim of this study was to investigate Napsin-A, NTRK-1, NTRK-2, Desmoglein-3, and Desmocollin-3 in the differential diagnosis and prognosis of nonsmall cell lung cancer. Materials and methods: The expression of Napsin-A, NTRK-1, NTRK-2, and Desmoglein-3 was examined by immunohistochemistry in 50 squamous cell carcinomas and 50 adenocarcinomas. Desmocollin-3 was investigated in 29 squamous cell carcinoma and 29 adenocarcinoma cases. Associations between expression profiles of Napsin-A, NTRK-1, NTRK-2, Desmoglein-3, and Desmocollin-3 in lung cancers and clinicopathological variables were analyzed. Results: Napsin-A staining was statistically significant in detecting adenocarcinomas versus squamous cell carcinomas. The sensitivity of Napsin-A for adenocarcinomas was 96% and the specificity was 100%. NTRK-2 and Desmocollin-3 staining were statistically significant in detecting squamous cell carcinomas versus adenocarcinomas. Desmoglein-3, Napsin-A, and NTRK-2 had no effect on survival. Disease-free survival time was significantly shorter in cases that were moderately positive with NTRK-1. Conclusion: Our data suggest that Napsin-A, NTRK-2, and Desmocollin-3 are useful markers in the differentiation of nonsmall cell lung cancer. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

5. Immunohistochemical expression of β-catenin, E-cadherin, cyclin D1 and c-myc in benign trichogenic tumors.

Author

Demirkan, Neşe Çallı, Bir, Ferda, Erdem, Özlem, and Düzcan, Ender

Subjects
*IMMUNOHISTOCHEMISTRY, *CADHERINS, *TUMORS, *GENETIC mutation, *CELL adhesion molecules, *GENE expression
Abstract

Background: β-catenin gene mutations have been reported in vast majority of pilomatrixomas (PMXs). β-catenin, a component of the adhesion molecules of the cytoskeleton, is degraded at the cytoplasm. Excess cytoplasmic β-catenin enters into the nucleus and activates the transcription of several genes encoding c-myc, cyclin D1 and others. Sublocation of β-catenin has been demonstrated by immunohistochemistry. The aim of this study was to determine the role of β-catenin-related proteins in various benign trichogenic tumors. Methods: We investigated the expression of β-catenin, E-cadherin, c-myc and cyclin D1 immunohistochemically, and the expression of these molecules were compared between two groups consisting of 12 PMXs and 12 other benign trichogenic tumors (OBTTs). Results: In PMX group, nuclear and/or cytoplasmic expression of β-catenin was associated with a loss of membranous expression of E-cadherin (p = 0.002). In OBTT group, a membranous expression of E-cadherin and β-catenin was observed, and there was a stronger nuclear immunoreactivity of cyclin D1 compared with PMX group (p = 0.006). Conclusions: In PMX, nuclear and/or cytoplasmic β-catenin expression of tumoral cells is not related with β-catenin-related gene expressions (c-myc or cyclin D1). The molecular behaviour of OBTTs is clearly different from that of PMXs in terms of to E-cadherin and β-catenin expression. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

6. The aid of new immunohistochemical markers in differantial diagnosis of non small cell lung carcinomas

Author

Çeliker, Duygu, Bir, Ferda, and Patoloji Anabilim Dalı

Subjects
Diagnosis-differential, Carcinoma, Diagnosis, Pathology, Patoloji, Carcinoma-non small cell-lung, Immunohistochemistry, Biomarkers-tumor
Abstract

Bu çalışmada, immunohistokimyasal Napsin-A, NTRK-1, NTRK-2, Desmoglein-3 ve Desmocollin-3 ekspresyonunun küçük hücreli dışı akciğer kanserlerinin ayırıcı tanısına katkısı, bu antikorlar ile birlikte çeşitli kliniko patolojik değişkenlerin prognoz üzerine etkisi araştırıldı.İmmunohistokimyasal olarak Napsin-A, NTRK-1, NTRK-2 ve Desmoglein-3 antikorları kullanılarak 50 skuamöz hücreli karsinom, 50 adenokarsinom olgusu, Desmocollin-3 ile 29 skuamöz hücreli karsinom, 29 adenokarsinom olgusu incelendi. Tüm olguların klinik izlem verilerine ulaşıldı. Hastaların takip süreleri 1-76 ay arasında değişmekteydi. Napsin-A ile adenokarsinomlu olguların 47'sinde (%94) değişen oranlarda granüler intrasitoplazmik pozitif boyanma izlenirken, 50 skuamöz hücreli karsinom olgusunun hiçbirinde boyanma görülmedi. Napsin-A'nın adenokarsinomlar için sensitivitesi %96, spesifitesi %100 tespit edildi. Napsin-A'nın skuamöz hücreli karsinom'lar için sensitivitesi ise %0, spesifitesi %4 bulundu. İstatistiksel olarak tümör hücrelerinde Napsin-A boyanması, gruplar arasında adenokarsinom lehine istatistiksel olarak anlamlı bulundu (p= 0.000).NTRK-1 ile 100 olgunun tümünde değişen oranlarda çoğu alanda sitoplazmik, tek tük nükleer boyanma izlendi. NTRK-1 pozitifliği açısından 2 grup arasında istatistiksel olarak anlamlı fark saptanmadı (p>0.05).NTRK-2 ile skuamöz hücreli karsinomların 47'sinde (%94) değişen oranlarda, sitoplazmik ve nükleer boyanmalar izlendi. Adenokarsinomların ise 32'sinde (%64) boyanma görülürken, 17'sinde (%34) boyanma izlenmedi. NTRK-2'nin skuamöz hücreli karsinomlar için sensitivitesi %96, spesifitesi %34 tespit edildi. NTRK-2'nin adenokarsinomlar için sensitivitesi ise %66, spesifitesi %4 bulundu. NTRK-2 ile tümör tipi arasındaki ilişki incelendiğinde 2 grup arasında skuamöz hücreli karsinom lehine istatistiksel olarak anlamlı fark saptandı (p=0.000).Desmoglein-3 ile tümör tipi istatistiksel olarak incelendiğinde skuamöz hücreli karsinomların 47'sinde (%94) değişen oranlarda, sitoplazmik ve nükleer boyanmalar izlendi. Adenokarsinomların ise 46'sında (%92) boyanma görüldü. Desmoglein-3'ün skuamöz hücreli karsinomlar için sensitivitesi %94, spesifitesi %8 tespit edildi. Desmoglein-3'ün adenokarsinomlar için sensitivitesi ise %92, spesifitesi %6 bulundu ve 2 grup arasında istatistiksel olarak anlamlı fark saptanmadı (p>0.05).Desmocollin-3, 29 skuamöz hücreli karsinomun 28'inde (%96.6) değişen oranlarda, genelde sitoplazmik, yer yer belirgin membranöz boyandı. Yirmidokuz adenokarsinom olgusunun ise 19'unda (%65.5) boyanma görüldü. Desmocollin-3'ün skuamöz hücreli karsinomlar için sensitivitesi %96.5, spesifitesi %34.4 tespit edildi. Desmocollin-3'ün adenokarsinomlar için sensitivitesi ise %65.5, spesifitesi %3 bulundu. Desmocollin-3 ile tümör tipi incelendiğinde 2 grup arasında skuamöz hücreli karsinom lehine istatistiksel olarak anlamlı fark bulundu (p=0.003).Bu çalışmada kliniko-patolojik parametrelerden evre dışındakiler ile sağkalım arasında anlamlı bir ilişki saptanmadı. Ancak evre I'de olan olgularda prognozun daha iyi olduğu görüldü (p=0.000). NTRK-1 boyanma indeksi ve kliniko-patolojik parametreler incelendiğinde NTRK-1 orta-şiddetli pozitif olan olgularda prognozun daha kötü olduğu tespit edildi (p=0.04).Sonuç olarak bu çalışmada diğer değişkenlerden bağımsız olarak evre-I'de olmanın diğer evrelere göre sağkalımı önemli oranda arttırdığı bulunmuştur. Bu da bize erken evrede tanı koymanın önemini vurgulamaktadır. Bulgularımız özellikle, mevcut boyalarla ayırıcı tanısı yapılamayan, küçük hücreli dışı akciğer kanseri-başka türlü sınıflandırılamayan tanısı alan olgularda rutinde kullanılan p63, TTF-1 ve müsin özel boyalarının yanı sıra Napsin-A, NTRK-2 ve desmocollin-3'ün de panele eklenebileceğini düşündürmektedir. The aim of this study was to investigate the aid of immunohistochemical ekspression of Napsin-A, NTRK-1, NTRK-2, Desmoglein-3 and Desmocollin-3 in differential diagnosis of non small cell lung carcinoma, effects of these markers and other clinicopathologic parameters to the prognosis.Expression of Napsin-A, NTRK-1, NTRK-2 and Desmoglein-3 in 50 squamous cell carcinoma and 50 adenocarcinoma were investigated immunohistochemically. Desmocollin-3 is immunohistochemically investigated only in 29 squamous cell carcinoma and 29 adenocarcinoma. Clinical follow-up data of all patients were able to reach. The survival time was ranging from 1 to 76 months.Ninety four percent of adenocarcinomas showed varying degrees of positivity with Napsin-A but none of the squamous cell carcinomas were positive with this marker. The sensitivity of Napsin-A was %96, spesifity was %100 for adenocarcinomas. Napsin-A staining was statistically significant for favoring adenocarcinoma than squamous cell carcinoma (p= 0.000).Variable degrees of positivity detected with NTRK-1 in all cases. There was no statistically significant differences with NTRK-1 staining between two groups (p>0.05).We observed varying proportions of cytoplasmic and nuclear staining in 47 (%94) of squamous cell carcinomas with NTRK-2. While 32 (%64) of the adenocarcinomas showed positivity with this marker 17 (%32) of them was negative. The sensitivity of NTRK-2 was %94, spesifity was %36 for squamous cell carcinoma. The sensitivity of NTRK-2 was %64, spesifity was %6 for adenocarcinomas. Napsin-A staining was statistically significant for favoring squamous cell carcinoma than adenocarcinoma (p= 0.000).When cases were evaluated for Desmoglein-3 staining, 47 of 50 (%94) squamous cell carcinomas and 46 of 50 (%92) squamous cell carcinomas were positive. The sensitivity of Desmoglein-3 was %94 for squamous cell carcinoma, %92 for adenocarcinoma. The spesivity was %8 and %6 respectively and there was no statistically significant differences with Desmoglein-3 staining between two groups (p>0.05).Desmocollin-3 was generally cytoplasmic, occasionally nuclear positive in 28 of 29 (%96.6) squamous cell carcinomas. Positive staining was detected in 19 of 29 (%65.5) adenocarcinomas. The sensitivity of Desmocollin-3 was %96.5 for squamous cell carcinoma, %65.5 for adenocarcinoma. The spesivity was %34.4 and %3.5 respectively. Desmocollin-3 staining was statistically significant favor squamous cell carcinomas (p=0.003).In this study, there was no correlation between clinicopathological variables and overall survival, except stage of the tumor. Stage I tumors had better prognosis than others (p=0.000). When NTRK-1 staining and clinicopathological variables examined together, we detected that NTRK-1 moderate-strong positive cases had worse prognosis (p=0.04).Our data suggested that when differential diagnosis is difficult in cases that seems to be non small cell lung carcinoma-not otherwise spesified, Napsin-A, NTRK-2 and desmocollin-3 can be useful markers additional to TTF-1, p63 and musicarmine in differentiating these tumours as squamous cell carcinoma or adenocarcinoma. 120

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results